SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that Vitaros®, the Company’s NexACT-based alprostadil product, significantly promoted healing of deep tissue wounds. Specifically, in a pig model, subjects with deep tissue wounds that were administered 200 mcgs of Vitaros healed four times faster than those receiving placebo over a 21-day period. This deep-seeded, wound healing pig model is widely regarded as the gold standard for pre-clinical testing of efficacy of wound-healing treatments. Vitaros is currently in late-stage development for the treatment of erectile dysfunction.
